Approval · Notice of Compliance 14849 · 2013
EXELON PATCH: Notice of Compliance 14849
Issued October 23, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14849
- Date
- October 23, 2013
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a new manufacturing site and synthetic route for dimetol, a significant intermediate in the manufacture of rivastigmine drug substance
- Therapeutic class
- Cholinesterase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON PATCH | Not yet assigned | — |
Medicinal ingredients
- RIVASTIGMINE 9 MG per PATCH
- RIVASTIGMINE 18 MG per PATCH